Clinical Research Directory
Browse clinical research sites, groups, and studies.
Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants
Sponsor: Aristotle University Of Thessaloniki
Summary
The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).
Official title: Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants: A Randomized Controlled Trial (The PRELUDE Trial)
Key Details
Gender
All
Age Range
24 Weeks - 29 Weeks
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2025-03-04
Completion Date
2027-03-01
Last Updated
2026-06-17
Healthy Volunteers
No
Conditions
Interventions
Enteral supplementation with ARA and DHA (in a 2:1 ratio) in addition to standard care and feeding
The intervention group will receive enteral supplementation containing arachidonic acid (ARA) and docosahexaenoic acid (DHA) in a 2:1 ratio, in addition to standard care and feeding. Supplementation will begin within the first three days of life and will continue until 36 weeks postmenstrual age.
Standard care and feeding
The control group will receive routine clinical care and nutritional support according to current neonatal unit protocols, without additional ARA/DHA supplementation.
Locations (1)
Papageorgiou General Hospital
Thessaloniki, Greece